|
Abraxis BioScience Receives Final Approval for Fosphenytoin Sodium Injection, USP
|
08-06-2007 |
|
Abraxis BioScience Receives FDA Approval for Caffeine Citrate Injection USP, 20 mg/mL
|
08-02-2007 |
|
Abraxis BioScience Acquires Manufacturing Facility from Watson
|
07-31-2007 |
|
Abraxis BioScience and the California NanoSystems Institute Announce Partnership for Collaborative Research in the Development of New Nanobiotechnologies
|
07-26-2007 |
|
Abraxis BioScience and Biocon Limited Announce Licensing Agreement for G-CSF in North America and the European Union
|
07-19-2007 |
|
Abraxis BioScience Announces Date for Second Quarter Financial Results and Investor Conference Call
|
07-16-2007 |
|
Abraxis BioScience Announces Plan to Separate Into Two Independent Public Companies
|
07-02-2007 |
|
Abraxis BioScience Exclusively Licenses Intellectual Property Portfolio Designed to Personalize Treatment for Colorectal Cancer from the University of Southern California
|
06-19-2007 |
|
Abraxis BioScience to Present at the Goldman Sachs 28th Annual Global Healthcare Conference
|
06-07-2007 |
|
ABRAXANE Demonstrates Longer Progression-Free Survival versus Taxotere in the Treatment of First-Line Metastatic Breast Cancer
|
06-02-2007 |
Print this page
RSS Feeds
Media Relations Contact